Cassava Sciences, Inc.

NasdaqCM SAVA

Cassava Sciences, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -5,733.01%

Cassava Sciences, Inc. EBITDA Margin is -5,733.01% for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: SAVA

Cassava Sciences, Inc.

CEO	Mr. Richard Jon Barry
IPO Date	July 14, 2000
Location	United States
Headquarters	7801 North Capital of Texas Highway
Employees	29
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key trends

Past 5 years